What does others — financial royalty assets, allowance mean?

This metric reflects the cumulative valuation adjustments or reserves established against the gross carrying value of royalty assets within the 'Others' segment. It accounts for potential impairments, credit risks, or changes in the expected recoverability of future royalty streams associated with these specific licensed technologies. An increase in this allowance typically signals management's assessment of heightened risk or diminished commercial prospects for the underlying drug programs.

Ligand Pharmaceuticals LGND Others — Financial Royalty Assets, Allowance

Other product segments

Qarziba

$480K—

Similar metrics at other companies

NOVRoyalty — Contract With Customer Receivable Allowance For Credit Loss

$78M+144%

WECValuation Allowances And Reserves Charged To Cost And Expense

$35.7M+36.1%

SSNCValuation Allowances And Reserves Charged To Cost And Expense

$4.65M+20.8%

SCIValuation Allowances And Reserves Balance

$108.83M-8.5%

LYBOther — Valuation allowance

$21M+75.0%

KLICValuation Allowances And Reserves Balance

$68.78M+51.3%

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.51B+96.7%

Enterprise value$5.4B+95.4%

P/E35.9×—

P/S20.1×+4.6×

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsAllowance.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's others — financial royalty assets, allowance.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's others — financial royalty assets, allowance?: Ligand Pharmaceuticals (LGND) reported others — financial royalty assets, allowance of $214K in Q1 2026.
What does others — financial royalty assets, allowance mean?: This metric reflects the cumulative valuation adjustments or reserves established against the gross carrying value of royalty assets within the 'Others' segment. It accounts for potential impairments, credit risks, or changes in the expected recoverability of future royalty streams associated with these specific licensed technologies. An increase in this allowance typically signals management's assessment of heightened risk or diminished commercial prospects for the underlying drug programs.